• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predictors of low clopidogrel adherence following percutaneous coronary intervention.经皮冠状动脉介入治疗后氯吡格雷低依从性的预测因素。
Am J Cardiol. 2011 Sep 15;108(6):822-7. doi: 10.1016/j.amjcard.2011.04.034. Epub 2011 Jul 7.
2
Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.经皮冠状动脉介入治疗后氯吡格雷与质子泵抑制剂合用的效果。
Am J Cardiol. 2011 Mar 15;107(6):871-8. doi: 10.1016/j.amjcard.2010.10.073. Epub 2011 Jan 19.
3
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.氯吡格雷与阿司匹林预处理后长期治疗对接受经皮冠状动脉介入治疗患者的影响:PCI-CURE研究
Lancet. 2001 Aug 18;358(9281):527-33. doi: 10.1016/s0140-6736(01)05701-4.
4
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.阿司匹林和氯吡格雷反应对经皮冠状动脉介入术后心肌坏死的影响:BRIEF-PCI(经皮冠状动脉介入成功后静脉注射依替巴肽短期输注)试验子研究
JACC Cardiovasc Interv. 2008 Dec;1(6):654-9. doi: 10.1016/j.jcin.2008.08.017.
5
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.细胞色素P450 3A4代谢的他汀类药物对600毫克负荷剂量氯吡格雷抗血小板作用及择期冠状动脉支架置入患者临床结局的影响。
Thromb Haemost. 2008 Jan;99(1):174-81. doi: 10.1160/TH07-08-0503.
6
Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.诊断性冠状动脉造影后接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者中应用比伐卢定的疗效和安全性。
Catheter Cardiovasc Interv. 2010 Oct 1;76(4):513-24. doi: 10.1002/ccd.22546.
7
Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?非ST段抬高型急性冠脉综合征及经皮冠状动脉介入治疗中的血小板抑制剂:糖蛋白IIb/IIIa抑制剂、氯吡格雷,还是两者联用?
Vasc Health Risk Manag. 2006;2(1):39-48. doi: 10.2147/vhrm.2006.2.1.39.
8
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.急性冠状动脉综合征患者行经皮冠状动脉介入治疗时的双联(氯吡格雷标准剂量与双倍剂量和阿司匹林低剂量与高剂量)治疗(CURRENT-OASIS 7):一项随机析因试验。
Lancet. 2010 Oct 9;376(9748):1233-43. doi: 10.1016/S0140-6736(10)61088-4.
9
Assessing patient-reported outcomes and preferences for same-day discharge after percutaneous coronary intervention: results from a pilot randomized, controlled trial.评估经皮冠状动脉介入治疗后患者报告的当日出院结局及偏好:一项试点随机对照试验的结果
Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):186-92. doi: 10.1161/CIRCOUTCOMES.111.000069. Epub 2013 Mar 12.
10
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.经皮冠状动脉介入治疗后早期持续双重口服抗血小板治疗:一项随机对照试验。
JAMA. 2002 Nov 20;288(19):2411-20. doi: 10.1001/jama.288.19.2411.

引用本文的文献

1
Implementing a pharmacogenomic-driven algorithm to guide antiplatelet therapy among Caribbean Hispanics: a non-randomised clinical trial.实施基于药物基因组学的算法指导加勒比西班牙裔人群的抗血小板治疗:一项非随机临床试验。
BMJ Open. 2024 Sep 5;14(9):e084119. doi: 10.1136/bmjopen-2024-084119.
2
Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.在真实环境中,PCSK9 单克隆抗体与依折麦布相比的持久性和依从性。
Adv Ther. 2024 Jun;41(6):2399-2413. doi: 10.1007/s12325-024-02868-z. Epub 2024 Apr 30.
3
The need of a multicomponent guiding approach to personalize clopidogrel treatment.需要采用多组分指导方法来实现个体化氯吡格雷治疗。
Pharmacogenomics J. 2021 Apr;21(2):116-127. doi: 10.1038/s41397-020-00189-2. Epub 2020 Oct 9.
4
Adherence to prophylactic dual antiplatelet therapy in patients with acute coronary syndrome - A study conducted at a Saudi university hospital.急性冠状动脉综合征患者预防性双联抗血小板治疗的依从性——在沙特一所大学医院开展的一项研究。
Saudi Pharm J. 2020 Mar;28(3):369-373. doi: 10.1016/j.jsps.2020.01.018. Epub 2020 Feb 3.
5
Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up.替卡格雷与氯吡格雷在接受冠状动脉支架植入术患者中的临床药效学及长期疗效:一项为期5年随访的随机研究
Eur J Clin Pharmacol. 2018 Nov;74(11):1397-1403. doi: 10.1007/s00228-018-2532-3. Epub 2018 Aug 20.
6
Effect of acute coronary syndrome patients' education on adherence to dual antiplatelet therapy.急性冠状动脉综合征患者教育对双联抗血小板治疗依从性的影响
J Saudi Heart Assoc. 2017 Oct;29(4):252-258. doi: 10.1016/j.jsha.2017.02.003. Epub 2017 Mar 8.
7
Systematic reviews: causes of non-adherence to P2Y12 inhibitors in acute coronary syndromes and response to intervention.系统评价:急性冠状动脉综合征中不依从P2Y12抑制剂治疗的原因及干预反应
Open Heart. 2016 Oct 19;3(2):e000479. doi: 10.1136/openhrt-2016-000479. eCollection 2016.
8
Association of Medicare Part D low-income cost subsidy program enrollment with increased fill adherence to clopidogrel after coronary stent placement.医疗保险D部分低收入成本补贴计划的登记与冠状动脉支架置入术后氯吡格雷用药依从性增加之间的关联。
Pharmacotherapy. 2014 Dec;34(12):1230-8. doi: 10.1002/phar.1502. Epub 2014 Oct 14.
9
Predictors of medication adherence postdischarge: the impact of patient age, insurance status, and prior adherence.出院后药物依从性的预测因素:患者年龄、保险状况和先前依从性的影响。
J Hosp Med. 2012 Jul-Aug;7(6):470-5. doi: 10.1002/jhm.1940. Epub 2012 Apr 2.

本文引用的文献

1
Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults.高血压管理中药物依从性的障碍与决定因素:老年人药物依从性队列研究的视角
Med Clin North Am. 2009 May;93(3):753-69. doi: 10.1016/j.mcna.2009.02.007.
2
The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease.依从性评估器:一种简短的、用于评估患者对慢性病处方药依从性倾向的近端筛查工具。
Curr Med Res Opin. 2009 Jan;25(1):215-38. doi: 10.1185/03007990802619425.
3
New medication adherence scale versus pharmacy fill rates in seniors with hypertension.老年高血压患者的新型药物依从性量表与药房配药率对比
Am J Manag Care. 2009 Jan;15(1):59-66.
4
Predictive validity of a medication adherence measure in an outpatient setting.门诊环境中药物依从性测量的预测效度。
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54. doi: 10.1111/j.1751-7176.2008.07572.x.
5
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee.《美国心脏病学会/美国心脏协会经皮冠状动脉介入治疗指南2005年更新:2007年重点更新》:美国心脏病学会/美国心脏协会实践指南工作组报告:2007年写作组审查新证据并更新《美国心脏病学会/美国心脏协会经皮冠状动脉介入治疗指南2005年更新》,代表2005年写作委员会撰写
Circulation. 2008 Jan 15;117(2):261-95. doi: 10.1161/CIRCULATIONAHA.107.188208. Epub 2007 Dec 13.
6
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.药物洗脱支架置入术后噻吩并吡啶类药物治疗过早停药的患病率、预测因素及结果:PREMIER注册研究结果
Circulation. 2006 Jun 20;113(24):2803-9. doi: 10.1161/CIRCULATIONAHA.106.618066. Epub 2006 Jun 12.
7
Adherence to medications by patients after acute coronary syndromes.急性冠状动脉综合征后患者对药物的依从性。
Ann Pharmacother. 2005 Nov;39(11):1792-7. doi: 10.1345/aph.1G249. Epub 2005 Oct 4.
8
Adherence to medication.药物依从性
N Engl J Med. 2005 Aug 4;353(5):487-97. doi: 10.1056/NEJMra050100.
9
Secondary prevention of coronary heart disease: patient beliefs and health-related behaviour.冠心病的二级预防:患者信念与健康相关行为
J Psychosom Res. 2005 May;58(5):403-15. doi: 10.1016/j.jpsychores.2004.11.010.
10
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.药物洗脱支架成功植入后血栓形成的发生率、预测因素及转归
JAMA. 2005 May 4;293(17):2126-30. doi: 10.1001/jama.293.17.2126.

经皮冠状动脉介入治疗后氯吡格雷低依从性的预测因素。

Predictors of low clopidogrel adherence following percutaneous coronary intervention.

机构信息

Department of Epidemiology and Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

出版信息

Am J Cardiol. 2011 Sep 15;108(6):822-7. doi: 10.1016/j.amjcard.2011.04.034. Epub 2011 Jul 7.

DOI:10.1016/j.amjcard.2011.04.034
PMID:21741610
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3586559/
Abstract

Few data are available on factors associated with low adherence or early clopidogrel discontinuation after percutaneous coronary intervention (PCI). Patients (n = 284) were evaluated before hospital discharge after PCI to identify factors associated with low adherence to clopidogrel 30 days later. Adherence to daily medications before PCI was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8) and categorized as low (score <6), medium (score 6 to <8), or high (score 8). Low adherence to clopidogrel was defined as MMAS-8 score <6 (n = 21) or having discontinued clopidogrel (n = 11), which was ascertained during a 30-day interview after PCI. At 30 days after PCI, 11% of patients had low adherence to clopidogrel. Odds ratios (95% confidence intervals [CIs]) for low adherence to clopidogrel were 3.78 (1.09 to 13.1), 3.06 (1.36 to 6.87), 2.46 (0.97 to 6.27), and 3.36 (0.99 to 11.4) for patients who before PCI reported taking smaller doses of medication because of cost, had difficulty filling prescriptions, had difficulty reaching their primary physician, and were not comfortable asking their doctor for instructions, respectively. Odds ratios (95% CIs) for low clopidogrel adherence after PCI in patients with medium and low versus high adherence to daily medications before PCI were 6.13 (1.34 to 28.2) and 10.9 (2.46 to 48.7), respectively. The c-statistic associated with MMAS-8 scores before PCI for discriminating low clopidogrel adherence at 30 days after PCI was 0.733 (95% CI 0.650 to 0.852). In conclusion, adherence to daily medications before PCI may be a useful indicator for identifying patients who will have low clopidogrel adherence after PCI.

摘要

关于经皮冠状动脉介入治疗 (PCI) 后低依从性或早期氯吡格雷停药的相关因素,目前仅有少量数据。本研究入选了 284 例 PCI 术后出院前的患者,旨在明确与 30 天后氯吡格雷低依从性相关的因素。采用 8 项 Morisky 用药依从性量表 (MMAS-8) 评估 PCI 前的每日用药依从性,并分为低依从性(得分 <6)、中依从性(得分 6 至 <8)或高依从性(得分 8)。氯吡格雷低依从性定义为 MMAS-8 评分 <6(n = 21)或停药(n = 11),通过 PCI 后 30 天的访谈确定。PCI 后 30 天,11%的患者氯吡格雷依从性低。氯吡格雷低依从性的优势比(95%置信区间 [CI])分别为 3.78(1.09 至 13.1)、3.06(1.36 至 6.87)、2.46(0.97 至 6.27)和 3.36(0.99 至 11.4),分别对应于 PCI 前报告因费用而减少药物剂量、难以配药、难以联系主治医生和难以向医生咨询的患者。在中、低与高 PCI 前每日用药依从性患者中,PCI 后氯吡格雷低依从性的优势比分别为 6.13(1.34 至 28.2)和 10.9(2.46 至 48.7)。PCI 前 MMAS-8 评分预测 30 天后氯吡格雷低依从性的 C 统计量为 0.733(95%CI 0.650 至 0.852)。结论:PCI 前的每日用药依从性可能是识别 PCI 后氯吡格雷低依从性患者的有用指标。